References

10.1182/bloodadvances.2026020704 · 2026 · Admitted local publication

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

10.1038/s41375-022-01613-1 · 2022 · External reference

International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data

10.1182/blood.2022015850 · 2022 · External reference

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

10.1038/s41375-020-0917-7 · 2021 · External reference

Molecular international prognostic scoring system for myelodysplastic syndromes

10.1056/evidoa2200008 · 2022 · External reference

Molecular landscape of therapy-related myeloid neoplasms in patients previously treated for gynecologic and breast cancers

10.1097/hs9.0000000000000632 · 2021 · External reference

Therapy-related myeloid neoplasms: complex interactions among cytotoxic therapies, genetic factors, and aberrant microenvironment

10.1158/2643-3230.bcd-24-0103 · 2024 · External reference

Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms

10.1136/jmedgenet-2011-100674 · 2012 · External reference

Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia

10.1002/cncr.29615 · 2016 · External reference

Role of germline predisposition to therapy-related myeloid neoplasms

10.1007/s11899-022-00676-2 · 2022 · External reference